QMDT Quick Med Technologies Inc (CE)

Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that two posters highlighting the use of the Company's novel NIMBUS® technology will be presented at the joint 2012 Symposium on Advanced Wound Care / Wound Healing Society meeting taking place April 19-21, 2012 in Atlanta. This event is the premier meeting of physicians, researchers and other wound care specialists.

NIMBUS is the only non-leaching antimicrobial technology cleared by the U.S. Food and Drug Administration for wound care; other antimicrobial dressings rely on the release of chemicals to the wound bed that can impede the wound healing process. NIMBUS is non-toxic, long-lasting and not blocked by organics such as blood, exudates, urine and perspiration. By design, NIMBUS poses no risk of bacteria developing resistance. Quick-Med's novel NIMBUS antimicrobial technology is available in BIOGUARD® dressings marketed by Derma Sciences, Inc.

The posters to be presented are:

• Adoption of Antimicrobial Gauze Bandages for Standard Use in Heavily Exudating Wounds, presented by Bernd Liesenfeld, Ph.D. and Quick-Med Principal Scientist  
• Caution When Combining Wound Products, presented by Gregory Schultz, University of Florida Research Foundation Professor and past President of the Wound Healing Society.

The two posters exhibit the usefulness of NIMBUS antimicrobial technology in the field of wound care. Professor Schultz will discuss the use of BIOGUARD and other dressings in conjunction with other wound care products. BIOGUARD has great compatibility with other wound care products whereas some dressings can have negative effects when used with other wound care products. Clinicians report that they like the added safety of a non-leaching antimicrobial and the convenience of not having to worry about dressing chemistry and incompatibilities in an increasingly complex wound care environment.

Dr. Liesenfeld will provide an update on the use of BIOGUARD dressings at the Shands Hospital burn unit in Gainesville, Florida. Clinical performance of NIMBUS technology in BIOGUARD dressings in this most challenging of applications is clearly evidenced by the reduction of odor and bacterial colonization in the dressing apparent in the lack of staining leading to expanded use of BIOGUARD use at Shands.

Commenting on the presentations, Dr. Jerry Olderman, vice president of R&D at Quick-Med said, "We are delighted to report additional data in support of the use of our NIMBUS technology. NIMBUS is the first bound, antimicrobial wound dressing which does not release an antimicrobial into the wound like traditional wound dressings. Rather, NIMBUS creates a barrier that won't allow bacteria to penetrate the dressing or grow in the wound fluid only to be shed back into the wound."  

About the Symposium on Advanced Wound Care / Wound Healing Society

Now in its 25th year, the Symposium is the premier educational wound care program within this clinical field and is the largest annual gathering of wound care clinicians in the United States.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.

The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260

© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc. BIOGUARD® is a registered trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

CONTACT: Quick-Med Technologies, Inc.
         J. Ladd Greeno, CEO
         (888) 835.2211 Ext 102
         Email: lgreeno@quickmedtech.com